US Patent Office Grants McCord Research Endothelial Cell Treatment Patent - Applied Clinical Trials

ADVERTISEMENT

See our 2013 Buyers Guide Digital Edition.
US Patent Office Grants McCord Research Endothelial Cell Treatment Patent


US Patent Office Grants McCord Research Endothelial Cell Treatment Patent

PR Newswire

CORALVILLE, Iowa, July 21, 2014 /PRNewswire/ -- McCord Research, Inc. was recently granted a second US patent (U.S. Patent No. 8,796,315). This patent describes a method for accelerating wound closure to improve wound healing.  According to the inventor, Dr. McCord, this method includes administering or transplanting to individuals who require wound healing, a composition of an effective amount of hydroxytyrosol and oleuropein and cells derived from umbilical cord blood, such that the administration of the combination reduces the time required for wound healing by at least approximately 30% in comparison to treatment with just cells derived from umbilical cord blood alone.

McCord Research.

Endothelial cells form the inner lining of a blood vessel and provides an anticoagulant barrier between the vessel wall and blood. Endothelial cells have a vital role in wound repair especially for patients with vascular disease and diabetes.  The restoration of these cells allows for vital nutrients to be delivered to the skin and wound through the small network of capillaries that form at the dermal epidermal junction. The endothelial cells additionally regulate hemostasis, vasomotor tone, angiogenesis and vasculogenesis and immune and inflammatory responses. In addition, the endothelial cell plays a pivotal role in wound care. "Endothelial cell injury is the genesis of many pathologic states including atherosclerosis, loss of semi-permeable membrane function, and thrombosis. Restoring the viability of endothelial cells has far reaching health implications," stated Dr. McCord.

McCord Research is seeking worldwide patent protection for its wound care technology and looks forward to healing wounds on a global basis. The technology is currently being licensed under the Olivamine 10® brand name in the United States and Asia for the treatment of wounds in humans and animals.

McCord Research, Inc. corporate offices are located at 2769 Heartland Drive in Coralville, IA.
For further information call 319-358-5536 or www.mccordresearch.com.  

www.olivamine.com
www.mccordresearch.com
www.facebook.com/mccordresearch

For Further Information:
Darlene McCord, Ph.D., CEO, CSO
McCord Research/Pinnaclife, Inc.
inquire@mccordresearch.com
319-351-3201

Logo - http://photos.prnewswire.com/prnh/20120510/CG05130LOGO

SOURCE McCord Research, Inc.

ADVERTISEMENT

blog comments powered by Disqus

ADVERTISEMENT

UPCOMING CONFERENCES

8th Annual Forum on Transparency and Aggregate Spend 2014
Washington, DC
August 18-20, 2014

eSource Data in Clinical Investigations
Philadelphia, PA
August 20-21, 2014

Pharmacovigilance 2014
Philadelphia, PA
September 10-11, 2014

Collaborative Research Summit
Philadelphia, PA
October 15-16, 2014

See All Conferences >>

Survey
As it creates a plan to implement the US biosimilar pathway, should FDA:
Borrow heavily from EMA's pathway program?
Borrow lightly from EMA's pathway program?
Create entirely its own pathway program?
Borrow heavily from EMA's pathway program?
86%
Borrow lightly from EMA's pathway program?
6%
Create entirely its own pathway program?
7%
View Results
Untitled Document

Click here